Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial-Reference-Cited by-同舟云学术

Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial

Published:2019-11 Issue:11 Volume:30 Page:1831-1839
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Guo Y.,Ahn M.-J.,Chan A.,Wang C.-H.,Kang J.-H.,Kim S.-B.,Bello M.,Arora R.S.,Zhang Q.,He X.,Li P.,Dechaphunkul A.,Kumar V.,Kamble K.,Li W.,Kandil A.,Cohen E.E.W.,Geng Y.,Zografos E.,Tang P.Z.

Funder

Boehringer Ingelheim

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/advance-article-pdf/doi/10.1093/annonc/mdz388/30123474/mdz388.pdf

Reference22 articles.

1. Targeted therapies in squamous cell carcinoma of the head and neck;Gold;Cancer,2009

2. Immune checkpoint inhibition in head and neck cancer;Forster;Front Oncol,2018

3. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck;Seiwert;Ann Oncol,2014